Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/25/2025

Testicular Cancer Screening and Management

Patient Education and Awareness

  • Individuals with a family history of testicular cancer should be informed about their increased risk and educated on signs and symptoms, such as painless testicular mass, scrotal heaviness, and dull ache, emphasizing the importance of prompt medical attention for any testicular abnormalities, as recommended by the American Family Physician and American Cancer Society 1, 2
  • High-risk individuals, such as those with a family history of testicular cancer, may benefit from monthly self-examinations, although routine testicular self-examination is not recommended for the general population by the USPSTF 1, 2

Screening and Diagnostic Approaches

  • The USPSTF recommends against routine screening in asymptomatic males due to low incidence and high cure rates, with a Grade D recommendation 2
  • Testicular ultrasonography using a 7.5 MHz transducer is recommended for immediate evaluation of testicular abnormalities, along with serum tumor markers such as AFP, β-HCG, and LDH, as suggested by 3
  • Prompt referral to urology is recommended for any confirmed intratesticular mass, with radical inguinal orchiectomy for definitive diagnosis and initial treatment, as implied by standard approaches

Outcomes and Follow-up

  • Testicular cancer has excellent survival rates (>90%) even when detected at symptomatic stages, according to the American College of Physicians, as published in the Annals of Internal Medicine 2
  • Regular monitoring is essential for individuals diagnosed with testicular cancer, with abdominal imaging for at least 5 years, as suggested by unspecified guideline societies

Potential Pitfalls and Considerations

  • Delayed diagnosis can occur due to misclassifying testicular masses as epididymitis or attributing back pain from metastatic disease to musculoskeletal issues, highlighting the importance of prompt evaluation, as noted by 3
  • Over-screening may lead to unnecessary anxiety and procedures without improving outcomes, while neglecting symptoms can delay diagnosis, emphasizing the need for balanced approaches to screening and evaluation, as recommended by the USPSTF 2
  • Testicular cancer is most commonly diagnosed in males between the ages of 15 and 34 years, with a mean age at diagnosis of approximately 33 years, and an annual incidence of approximately 5.4-6.3 cases per 100,000 males, resulting in approximately 8,590-10,000 new cases diagnosed annually in the United States, as reported by 1, 2, 4
  • Established risk factors for testicular cancer development include prior history of testicular cancer, positive family history, cryptorchidism, testicular dysgenesis, infertility, Caucasian ethnicity, cannabis use, and genetic conditions such as Klinefelter syndrome, as identified by 4, 5

Diagnostic Evaluation and Management

  • Definitive diagnosis requires histological examination of the testicular mass removed by radical inguinal orchiectomy, with testicular ultrasound as the initial imaging modality of choice, and tumor markers (β-HCG, AFP, LDH) must be measured before orchiectomy, as recommended by 6, 7, 8
  • Initial treatment for pure seminoma is radical inguinal orchiectomy, as recommended by the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) 8, 4
  • Risk stratification for stage I disease is based on tumor size and rete testis involvement, with low, intermediate, and high risk categories having relapse risks of 12%, 15%, and 32%, respectively, as shown in the following table:
Risk Category Tumor Size Rete Testis Involvement Relapse Risk
Low <4 cm Absence 12%
High >4 cm Presence 32%
Intermediate - One risk factor present 15%
  • Management options for stage I disease include surveillance, adjuvant carboplatin, or adjuvant radiotherapy, with a disease-specific survival of 99% regardless of management strategy, according to the NCCN 4
  • For stage IIA-B, dogleg radiotherapy or chemotherapy can be used, while for stage IIC-III, chemotherapy with 3-4 cycles of BEP is recommended, as per the ESMO 8
  • Regular follow-up with abdominal imaging for at least 5 years is required for surveillance, and sperm banking should be discussed prior to chemotherapy or radiation treatment, as suggested by the NCCN and ESMO 8, 9